A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide.

Abstract

Methazolamide (MTA) is an antiglaucoma drug; however, there are many side effects of its systemic administration with insufficient ocular therapeutic concentrations. The aim of this study was to formulate MTA-loaded solid lipid nanoparticles (SLNs) and evaluate the potential of SLNs as a new therapeutic system for glaucoma. SLNs were prepared by a modified emulsion-solvent evaporation method and their physicochemical characteristics were evaluated. The pharmacodynamics was investigated by determining the percentage decrease in intraocular pressure. The ocular irritation was studied by Draize test. Despite a burst release of SLNs, the pharmacodynamic experiment indicated that MTA-SLNs had higher therapeutic efficacy, later occurrence of maximum action, and more prolonged effect than drug solution and commercial product. Formulation of MTA-SLNs would be a potential delivery carrier for ocular delivery, with the advantages of a more intensive treatment for glaucoma, lower in doses and better patient compliance compared to the conventional eye drops.

• Authors: Rui Li, Sunmin Jiang, Dongfei Liu, Xinyun Bi, Fengzhen Wang, Qing Zhang, Qunwei Xu
• Journal: Journal of microencapsulation (J Microencapsul) Vol. 28 Issue 2 Pg. 134-41 ( 2011) ISSN: 1464-5246 [Electronic] England
• PMID: 21142697 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Carbonic Anhydrase Inhibitors
• Lipids
• Methazolamide

Topics

• Animals
• Carbonic Anhydrase Inhibitors (chemistry, pharmacokinetics, pharmacology)
• Drug Delivery Systems
• Female
• Glaucoma (drug therapy)
• Humans
• Lipids (chemistry, pharmacokinetics, pharmacology)
• Male
• Methazolamide (chemistry, pharmacokinetics, pharmacology)
• Nanoparticles (chemistry)
• Rabbits